Terms: = Breast cancer AND MDM2, HDM2, 4193, ENSG00000135679, HDMX, MGC71221, hdm2, Q00987 AND Treatment
169 results:
1. Discovery of ganoderic acid A (GAA) PROTACs as mdm2 protein degraders for the treatment of breast cancer.
Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
[TBL] [Abstract] [Full Text] [Related]
2. Targeting G-rich sequence to regulate the transcription of murine double minute (MDM) genes in triple-negative breast cancers.
Feng Y; Xuan X; Hu Y; Lu J; Dong Z; Sun Z; Yao H; Hu L; Yin Q; Liu Y; Wang H
Eur J Med Chem; 2024 Mar; 267():116156. PubMed ID: 38295687
[TBL] [Abstract] [Full Text] [Related]
3. C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple-negative breast cancer.
Liao L; Deng L; Zhang YL; Yang SY; Andriani L; Hu SY; Zhang FL; Shao ZM; Li DQ
Clin Transl Med; 2023 Nov; 13(11):e1480. PubMed ID: 38009308
[TBL] [Abstract] [Full Text] [Related]
4. Actinomycin D synergizes with Doxorubicin in triple-negative breast cancer by inducing P53-dependent cell apoptosis.
Yang H; Li S; Li W; Yang Y; Zhang Y; Zhang S; Hao Y; Cao W; Xu F; Wang H; Du G; Wang J
Carcinogenesis; 2024 Apr; 45(4):262-273. PubMed ID: 37997385
[TBL] [Abstract] [Full Text] [Related]
5. Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.
Franco AFDV; Malinverni ACM; Waitzberg AFL
Pathol Res Pract; 2023 Dec; 252():154917. PubMed ID: 37977031
[TBL] [Abstract] [Full Text] [Related]
6. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
André F; Su F; Solovieff N; Hortobagyi G; Chia S; Neven P; Bardia A; Tripathy D; Lu YS; Lteif A; Taran T; Babbar N; Slamon D; Arteaga CL
Ann Oncol; 2023 Nov; 34(11):1003-1014. PubMed ID: 37673211
[TBL] [Abstract] [Full Text] [Related]
7. Sarcoma care in the era of precision medicine.
Wallander K; Öfverholm I; Boye K; Tsagkozis P; Papakonstantinou A; Lin Y; Haglund de Flon F
J Intern Med; 2023 Dec; 294(6):690-707. PubMed ID: 37643281
[TBL] [Abstract] [Full Text] [Related]
8. P53 status, and G2/M cell cycle arrest, are determining factors in cell-death induction mediated by ELF-EMF in glioblastoma.
Mehdizadeh R; Madjid Ansari A; Forouzesh F; Shahriari F; Shariatpanahi SP; Salaritabar A; Javidi MA
Sci Rep; 2023 Jul; 13(1):10845. PubMed ID: 37407632
[TBL] [Abstract] [Full Text] [Related]
9. Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic breast cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors.
Rao X; Chen Y; Beyrer J; Nash Smyth E; Morato Guimaraes C; Litchfield LM; Bowman L; Lawrence GW; Aggarwal A; Andre F
Clin Cancer Res; 2023 Sep; 29(17):3372-3383. PubMed ID: 37289194
[TBL] [Abstract] [Full Text] [Related]
10. Effect of Smilax spp. and Phellinus linteus combination on cytotoxicity and cell proliferation of breast cancer cells.
Chalertpet K; Sangkheereeput T; Somjit P; Bankeeree W; Yanatatsaneejit P
BMC Complement Med Ther; 2023 Jun; 23(1):177. PubMed ID: 37264344
[TBL] [Abstract] [Full Text] [Related]
11. Prion protein-dependent regulation of p53-mdm2 crosstalk during endoplasmic reticulum stress and doxorubicin treatments might be essential for cell fate in human breast cancer cell line, MCF-7.
Tuğrul B; Balcan E; Öztel Z; Çöllü F; Gürcü B
Exp Cell Res; 2023 Aug; 429(1):113656. PubMed ID: 37245583
[TBL] [Abstract] [Full Text] [Related]
12. Screening of natural product libraries in MCF7 cell line reveals the pro-apoptotic properties of β tetralone.
Shaikh N; Sivaram A; Vyas R
J Biomol Struct Dyn; 2024; 42(2):876-884. PubMed ID: 37014028
[TBL] [Abstract] [Full Text] [Related]
13. The inhibitory effect and mechanism of Resina Draconis on the proliferation of MCF-7 breast cancer cells: a network pharmacology-based analysis.
Lv Y; Mou Y; Su J; Liu S; Ding X; Yuan Y; Li G; Li G
Sci Rep; 2023 Mar; 13(1):3816. PubMed ID: 36882618
[TBL] [Abstract] [Full Text] [Related]
14. Targeted mdm2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative breast cancer.
Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
[TBL] [Abstract] [Full Text] [Related]
15. Downregulation of mdm2 by small interference RNA induces apoptosis and sensitizes MCF-7 breast cells to resveratrol.
Zhang NX; Ma JF; Li SQ; Yin Z; Li L
Chem Biol Drug Des; 2023 May; 101(5):1082-1088. PubMed ID: 36515454
[TBL] [Abstract] [Full Text] [Related]
16. p52-ZER6: a determinant of tumor cell sensitivity to mdm2-p53 binding inhibitors.
Li WF; Alfason L; Huang C; Tang Y; Qiu L; Miyagishi M; Wu SR; Kasim V
Acta Pharmacol Sin; 2023 Mar; 44(3):647-660. PubMed ID: 35995868
[TBL] [Abstract] [Full Text] [Related]
17. MIR4435-2HG Is a Potential Pan-cancer Biomarker for Diagnosis and Prognosis.
Zhong C; Xie Z; Zeng LH; Yuan C; Duan S
Front Immunol; 2022; 13():855078. PubMed ID: 35784328
[TBL] [Abstract] [Full Text] [Related]
18. A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in breast cancer.
Naeem M; Iqbal MO; Khan H; Ahmed MM; Farooq M; Aadil MM; Jamaludin MI; Hazafa A; Tsai WC
Molecules; 2022 May; 27(11):. PubMed ID: 35684353
[TBL] [Abstract] [Full Text] [Related]
19. Pimozide inhibits the growth of breast cancer cells by alleviating the Warburg effect through the P53 signaling pathway.
Li J; Qu P; Zhou XZ; Ji YX; Yuan S; Liu SP; Zhang QG
Biomed Pharmacother; 2022 Jun; 150():113063. PubMed ID: 35658233
[TBL] [Abstract] [Full Text] [Related]
20. Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors.
Timmerman DM; Eleveld TF; Sriram S; Dorssers LCJ; Gillis AJM; Schmidtova S; Kalavska K; van de Werken HJG; Oing C; Honecker F; Mego M; Looijenga LHJ
J Clin Oncol; 2022 Sep; 40(26):3077-3087. PubMed ID: 35442716
[TBL] [Abstract] [Full Text] [Related]
[Next]
